Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
| Autor: | Tayyaba Hasan, Rowland Illing, B. W. Pogue, M. T. Huggett, Marco Novelli, A. Gillams, SP Pereira, S. Mosse, Michael Jermyn, E. Kent, Sg Bown |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Porphyrins medicine.medical_treatment Photodynamic therapy Adenocarcinoma Necrosis 03 medical and health sciences 0302 clinical medicine Breast cancer Pancreatic cancer pancreatic adenocarcinoma medicine Humans Aged 030304 developmental biology 0303 health sciences verteporfin Photosensitizing Agents business.industry Skin photosensitivity Irreversible electroporation Middle Aged medicine.disease Verteporfin 3. Good health Surgery Pancreatic Neoplasms Radiation therapy photodynamic therapy Photochemotherapy Oncology 030220 oncology & carcinogenesis Clinical Study Disease Progression Feasibility Studies Female Radiology Skin cancer business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Background: Patients with pancreatic cancer have a poor prognosis apart from the few suitable for surgery. Photodynamic therapy (PDT) produces localised tissue necrosis but previous studies using the photosensitiser meso-tetrahydroxyphenylchlorin (mTHPC) caused prolonged skin photosensitivity. This study assessed a shorter acting photosensitiser, verteporfin. Methods: Fifteen inoperable patients with locally advanced cancers were sensitised with 0.4 mg kg−1 verteporfin. After 60–90 min, laser light (690 nm) was delivered via single (13 patients) or multiple (2 patients) fibres positioned percutaneously under computed tomography (CT) guidance, the light dose escalating (initially 5 J, doubling after each three patients) until 12 mm of necrosis was achieved consistently. Results: In all, 12 mm lesions were seen consistently at 40 J, but with considerable variation in necrosis volume (mean volume 3.5 cm3 at 40 J). Minor, self-limiting extrapancreatic effects were seen in multifibre patients. No adverse interactions were seen in patients given chemotherapy or radiotherapy before or after PDT. After PDT, one patient underwent an R0 Whipple's pancreaticoduodenectomy. Conclusions: Verteporfin PDT-induced tumour necrosis in locally advanced pancreatic cancer is feasible and safe. It can be delivered with a much shorter drug light interval and with less photosensitivity than with older compounds. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|